Drug Research
Syntegon and Vetter win PDA Drug Delivery Innovation Award for Versynta microBatch
Together with Vetter, an international pharmaceutical service provider for injectables, Syntegon (formerly Bosch Packaging Technology) has won the PDA Drug Delivery Innovation Award. In the...
Drug Research
Moderna Announces European Medicines Agency Authorizes Third Dose of COVID-19 Vaccine for Immunocompromised Individuals Aged 12 Years and Older
Moderna, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines announced that the European Medicines Agency (EMA) has authorized a third dose of...
Drug Research
TriLink BioTechnologies Extends EyeGene Partnership for COVID-19 Vaccine Development in South Korea
TriLink BioTechnologies, a Maravai LifeSciences company and a leader in the production of nucleic acids for research, diagnostics and therapeutics applications, announced that it expects...
Drug Research
Clarity and Evergreen enter Targeted Copper Theranostics manufacturing agreement for US clinical trials
Clarity Pharmaceuticals, an Australian-based clinical stage radiopharmaceutical company developing next-generation products to address the growing need in oncology, and Evergreen Theragnostics, Inc., a radiopharmaceutical contract...
Drug Research
Merck Licenses Foundational CRISPR Technology to Cellecta, Paving Path for Development of Next-Generation Treatments
Merck, a leading science and technology company, announced that its Life Science business sector has signed an agreement licensing its patented CRISPR-Cas9 technology to Cellecta,...
Drug Research
Phesi Big Data Analysis of Over 200,000 Hepatitis B and C Patients Identifies Typical Patient to Help Drive Forward Disease Elimination Goals
Phesi Inc., a data-driven provider of AI-powered clinical development analytics products and solutions, has analyzed data from 209,860 hepatitis B (HBV) and C (HCV) patients,...
Drug Research
Sanofi to focus its COVID-19 development efforts on the recombinant vaccine candidate
Recent positive interim results of Sanofi’s mRNA-based COVID-19 vaccine candidate Phase 1/2 study confirm the company’s platform robust capabilities and strategy in mRNA.
Taking into account...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.